Thomas et al. [30] reported that regorafenib, which is an inhibitor of VEGFR-1, − 2 and − 3 and tumor cell signaling kinases (RET, KIT, PDGFR, and Raf), yielded median PFS of 4.6 months in advanced sarcoma patients, which was almost the same as with pazopanib. Here, PDGFRB is linked to sarcoma.